2-(2-Hydroxyethoxy)-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-Hydroxyethoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₈H₁₆O₇
• 分子量: 224.21
• InChiKey: SMORULFPMBCEPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  120
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Production of steviol glycoside in recombinant hosts
  申请人：EVOLVA SA

  公开号：US10364450B2

  公开（公告）日：2019-07-30

  The invention relates to recombinant microorganisms and methods for producing steviol glycosides, glycosylated ent-kaurenol, and glycosylated ent-kaurenoic acid.

  本发明涉及重组微生物和生产甜菊糖苷、糖基化ent-kaurenol 和糖基化ent-kaurenoic acid 的方法。
• Mogrosides, compositions and their purification
  申请人：The Coca-Cola Company

  公开号：US10683323B2

  公开（公告）日：2020-06-16

  Novel mogrosides and methods for heir purification are provided herein. In addition, compositions comprising said novel mogrosides and methods for preparing the same are provided. The present invention relates generally to novel mogrosides, as well as compositions comprising such novel mogrosides, including consumables. The present invention further extends to methods of purifying such novel mogrosides, methods for preparing compositions (e.g., consumables) comprising such novel mogrosides and methods of enhancing the flavor or sweetness of consumables using these novel mogrosides.

  本文提供了新颖的mogrosides及其纯化方法。此外，本发明还提供了包含所述新型 mogrosides 的组合物及其制备方法。本发明一般涉及新型mogrosides，以及包含这种新型mogrosides的组合物，包括耗材。本发明进一步扩展到纯化这种新型mogrosides的方法、制备包含这种新型mogrosides的组合物（例如，耗材）的方法以及使用这种新型mogrosides增强耗材风味或甜味的方法。
• Novel Mogrosides and Uses of the Same
  申请人：The Coca-Cola Company

  公开号：US20220142216A1

  公开（公告）日：2022-05-12

  Mogrosides containing non-glucose glycosides are provided herein. Compositions, including consumables comprising the novel mogrosides described herein, are also provided.
• [EN] METHODS OF CONTROLLING ACUTE INFLAMMATORY RESPONSE<br/>[FR] MÉTHODES DE RÉGULATION DE LA RÉPONSE INFLAMMATOIRE AIGUË
  申请人：ENDOCYTE INC

  公开号：WO2021242752A1

  公开（公告）日：2021-12-02

  The present disclosure relates to compositions and methods for use in targeted drug delivery. More particularly, the disclosure is directed to cell-surface receptor binding conjugates for use in controlling or treating inflammatory responses, such as systemic inflammatory response syndrome, cytokine release syndrome, and the like. More particularly, the disclosure is directed to cell-surface receptor binding conjugates for use in controlling or treating COVID-19.